nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

7. Therapiemonitoring und Rezidivstaging

verfasst von : Prof. Dr. med. Rotem Shlomo Lanzman

Erschienen in: MR- und PET-Bildgebung der Prostata

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In Abhängigkeit vom gewählten Therapiekonzept werden unterschiedliche Anforderungen an die Rezidivdiagnostik und das Therapiemonitoring des Prostatakarzinoms gestellt. Die mpMRT gewinnt dabei insbesondere in der Lokalrezidivdiagnostik nach radikaler Prostatektomie oder Strahlentherapie sowie im Rahmen der aktiven Überwachung niedriggradiger Prostatakarzinome zunehmend an Bedeutung. Einen weiteren wesentlichen Bestandteil der Rezidivdiagnostik stellt neben der Skelettszintigraphie insbesondere das PET-CT dar. Durch den Einsatz innovativer PET-Tracer (z. B. 68Ga-PSMA) kann dabei die Detektionsrate von Rezidiven auch bei niedrigen PSA-Werten verbessert werden. Inwiefern der Einsatz von hochmodernen MR/PET-Systemen die Rezidivdiagnostik weiter verbessert kann bleibt abzuwarten.

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K (2015) Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 67:839–849

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET-CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20

Allen SD, Thompson A, Sohaib SA (2008) The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol 18:1281–1291

Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 3.1. AWMF-Register-Nummer 043/022OL 2014

Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA et al (2016) Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol 69:41–49

Beerlage HP, Thuroff S, Madersbacher S, Zlotta AR, Aus G, De Reijke TM, De la Rosette JJ (2000) Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 37:2–13

Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C (2013) Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis. J Contemp Brachytherapy 5:210–214

Brogsitter C, Zophel K, Kotzerke J (2013) ¹⁸F-Choline, ¹¹C-choline and ¹¹C-acetate PET-CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40 Suppl 1:S18–27

Casciani E, Bertini L, Gualdi G, Sciarra A, Panebianco V, Salciccia S et al (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600. Eur Urol 55:e2–3; author reply e4–5

Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, Gualdi GF (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190:1187–1192

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S et al (2011) Is there a role for (11)C-choline PET-CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38:55–63

Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S (2014) 11C-choline PET-CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 41:878–886

Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, Van Poppel H, Scardino PT, Shariat SF (2012) Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 61:961–971

Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP Jr (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387–1391

Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, Nanni C, Colletti PM, Rubello D (2013) Role of (18)F-choline PET-CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 40:1356–1364

Cirillo S, Petracchini M, D’Urso L, Dellamonica P, Illing R, Regge D, Muto G (2008) Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int 102:452–458

Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769

Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M 3rd, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448

Conti SL, Dall’era M, Fradet V, Cowan JE, Simko J, Carroll PR (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181:1628–1633; discussion 1633–1634

Costa DN, Pedrosa I, Donato F Jr, Roehrborn CG, Rofsky NM (2015) MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. Radiographics 35:696–708

Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA (2000) Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163:1085–1089

Da Rosa MR, Milot L, Sugar L, Vesprini D, Chung H, Loblaw A, Pond GR, Klotz L, Haider MA (2015) A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging 41:220–225

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32–38; discussion 38–39

De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM (2010) Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 194:1427–1443

Decker G, Murtz P, Gieseke J, Traber F, Block W, Sprinkart AM, Leitzen C, Buchstab T, Lutter C, Schuller H et al (2014) Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol 113:115–120

Dotan ZA, Bianco FJ Jr, Rabbani F, Eastham JA, Fearn P, Scher HI, Kelly KW, Chen HN, Schoder H, Hricak H et al (2005) Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23:1962–1968

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M et al (2015) Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET-CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668–674

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M et al (2016) Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol

Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407–2411

Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, Marks LS (Serial MRI in Active Surveillance of Prostate Cancer: Incremental Value. J Urol 2015.

Fichtner J (2006) PSA recurrence following radical prostatectomy and radiotherapy. Urologe A 45:1255–1256, 1258–1259

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439

Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U et al (2015) PSMA PET-CT with Glu-urea-Lys-(Ahx)-[(6)(8)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:1794–1800

Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94:299–302

Guarneri A, Botticella A, Ragona R, Filippi AR, Munoz F, Casetta G, Gontero P, Tizzani A, Ricardi U (2013) Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World J Urol 31:411–415

Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430

Hinnen KA, Monninkhof EM, Battermann JJ, Van Roermund JG, Frank SJ, Van Vulpen M (2012) Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys 82:883–888

Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ et al (2006) Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 107:1496–1502

Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS (2014) Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol 192:385–390

Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607–611

Khan MA, Han M, Partin AW, Epstein JI, Walsh PC (2003) Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62:86–91; discussion 91–92

Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190:1180–1186

Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35:246–252

Kitajima K, Hartman RP, Froemming AT, Hagen CE, Takahashi N, Kawashima A (2015) Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI. AJR Am J Roentgenol 205:807–816

Kupelian PA, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W et al (2005) Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61:415–419

McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, Morandeau L (2011) ¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38:14–22

Menard C, Smith IC, Somorjai RL, Leboldus L, Patel R, Littman C, Robertson SJ, Bezabeh T (2001) Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 50:317–323

Mohsen B, Giorgio T, Rasoul ZS, Werner L, Ali GR, Reza DK, Ramin S (2013) Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112:1062–1072

Morgan VA, Riches SF, Giles S, Dearnaley D, DeSouza NM (2012) Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol 198:596–602

Morgan VA, Riches SF, Thomas K, Vanas N, Parker C, Giles S, Desouza NM (2011) Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 84:31–37

Motamedinia P, Richard JL, McKiernan JM, DeCastro GJ, Benson MC (2012) Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. Urology 80:1070–1074

Mottet BJN, Briers E, Van den Bergh RCN, Bolla M, Van Casteren NJ, Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, Van der Poel H, Van der Kwast TH, Rouviere O, Wiegel T (2015) Guidelines on Prostate Cancer. The Uropean Association of Urology

Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, De KJ, Freedland SJ (2004) Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260–2264

Osmonov DK, Heimann D, Janssen I, Aksenov A, Kalz A, Juenemann KP (2014) Sensitivity and specificity of PET-CT regarding the detection of lymph node metastases in prostate cancer recurrence. Springerplus 3:340

Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, Tombolini V, Catalano C (2013) Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 23:1745–1752

Park SY, Kim CK, Park BK, Park W, Park HC, Han DH, Kim B (2012) Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 83:749–755

Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, De la Taille A (2010) Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance – does the risk of misclassification vary according to biopsy criteria? J Urol 183:539–544

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597

Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62–69

Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553

Rinnab L, Mottaghy FM, Simon J, Volkmer BG, De Petriconi R, Hautmann RE, Wittbrodt M, Egghart G, Moeller P, Blumstein N et al (2008) [11C]Choline PET-CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81:191–197

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–674

Romero-Otero J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, Vilaseca A, Carlsson SV, Touijer KA (2015) Active surveillance for prostate cancer. Int J Urol

Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, Gelet A, Lyonnet D (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor – correlation with biopsy findings. Urology 63:922–927

Rouviere O, Vitry T, Lyonnet D (2010) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20:1254–1266

Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 200:W361–368

Rud E, Baco E, Lien D, Klotz D, Eggesbo HB (2014) Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies. AJR Am J Roentgenol 202:W241–246

Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238:176–183

Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S et al (2008) Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 102:446–451

Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, Villers A, Hugosson J, Moore CM (2015) Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 67:627–636

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600

Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology 231:379–385

Sengoz M, Abacioglu U, Cetin I, Turkeri L (2003) PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment. Eur Urol 43:473–437

Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Schuller P, Schafer U, Micke O, Panke JE, Willich N (2005) PSA course after definitive high-dose radiotherapy of localized prostate cancer. Anticancer Res 25:1555–1557

Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M et al (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64:713–719

Smith CD (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281:1598–1604

Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, Jorcano S, Zaugg K, Seifert HH, Veit-Haibach P et al (2012) Clinical impact of 18F-choline PET-CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 39:936–943

Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B et al (2013) Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119:3359–3366

Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978

Tamada T, Sone T, Jo Y, Hiratsuka J, Higaki A, Higashi H, Ito K (2011) Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 197:408–414

Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L (2014) Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET-CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 52:725–733

Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser T, Weishaupt D, Kurhanewicz J, Steurer J (2009) Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 55:575–590

Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M (2015) Imaging of prostate cancer with PET-CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging 5:96–108

Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, Shukla-Dave A, Eastham J, Scardino P, Hricak H (2012) Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 188:1732–1738

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R (2007) ¹⁸F-choline and/or ¹¹C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 99:1415–1420

Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C et al (2015) Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol 33:202 e1–7

Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J (2010) Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 256:485–492

Wibmer AG, Burger IA, Sala E, Hricak H, Weber WA, Vargas HA (2016) Molecular Imaging of Prostate Cancer. Radiographics 36:142–159

Woodrum DA, Kawashima A, Karnes RJ, Davis BJ, Frank I, Engen DE, Gorny KR, Felmlee JP, Callstrom MR, Mynderse LA (2013) Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. Urology 82:870–875

Titel: Therapiemonitoring und Rezidivstaging
verfasst von: Prof. Dr. med. Rotem Shlomo Lanzman
Verlag: Springer Berlin Heidelberg
Buch: MR- und PET-Bildgebung der Prostata
Print ISBN: 978-3-662-50467-3

Electronic ISBN: 978-3-662-50468-0

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-50468-0_7

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

7. Therapiemonitoring und Rezidivstaging

Zusammenfassung

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie